ClinicalTrials.gov
public full text
Public Domain
DHA Brain Delivery Trial
Carrying the APOE ɛ4 allele is the strongest genetic risk factor for developing Alzheimer's disease. The goal of this project is to identify whether carrying the APOE ɛ4 allele is associated with reduced delivery of DHA to the brain. This information will help us identify the target population that could benefit from DHA supplementation to prevent cognitive decline.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old#850740
- AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)#1140807
- APOE ε4 carriership status enhances age-related changes in Alzheimer’s disease plasma biomarkers concentrations#231420
- Effect of Consuming a Mixture of Extracts and DHA on the Mild Cognitive Impairment#1172688
- What is the cognitive function status and associated factors among adult patients with asthma in northwest Ethiopia? A multicentre hospital-based cross-sectional study.#322840
Record · ID 801825
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive